Wells Fargo’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $448K | Buy |
46,678
+18,253
| +64% | +$175K | ﹤0.01% | 3872 |
|
|
2025
Q1 | $178K | Buy |
28,425
+2,909
| +11% | +$18.2K | ﹤0.01% | 4348 |
|
|
2024
Q4 | $207K | Buy |
25,516
+7,462
| +41% | +$60.6K | ﹤0.01% | 4296 |
|
|
2024
Q3 | $326K | Buy |
18,054
+739
| +4% | +$13.4K | ﹤0.01% | 3896 |
|
|
2024
Q2 | $178K | Buy |
17,315
+5,710
| +49% | +$58.8K | ﹤0.01% | 4234 |
|
|
2024
Q1 | $123K | Buy |
11,605
+715
| +7% | +$7.59K | ﹤0.01% | 4407 |
|
|
2023
Q4 | $99.4K | Buy |
10,890
+3,616
| +50% | +$33K | ﹤0.01% | 4496 |
|
|
2023
Q3 | $75.4K | Sell |
7,274
-2,324
| -24% | -$24.1K | ﹤0.01% | 4609 |
|
|
2023
Q2 | $137K | Buy |
9,598
+4,872
| +103% | +$69.8K | ﹤0.01% | 4564 |
|
|
2023
Q1 | $33.7K | Buy |
+4,726
| New | +$33.7K | ﹤0.01% | 5082 |
|
|
2022
Q4 | – | Sell |
-407
| Closed | -$5K | – | 7295 |
|
|
2022
Q3 | $5K | Sell |
407
-192
| -32% | -$2.36K | ﹤0.01% | 5586 |
|
|
2022
Q2 | $5K | Sell |
599
-1,006
| -63% | -$8.4K | ﹤0.01% | 5720 |
|
|
2022
Q1 | $22K | Sell |
1,605
-7,188
| -82% | -$98.5K | ﹤0.01% | 5638 |
|
|
2021
Q4 | $173K | Buy |
+8,793
| New | +$173K | ﹤0.01% | 4972 |
|
|
2021
Q2 | – | Sell |
-3,527
| Closed | -$132K | – | 6894 |
|
|
2021
Q1 | $132K | Sell |
3,527
-7,762
| -69% | -$290K | ﹤0.01% | 5026 |
|
|
2020
Q4 | $375K | Buy |
11,289
+2,662
| +31% | +$88.4K | ﹤0.01% | 4636 |
|
|
2020
Q3 | $316K | Sell |
8,627
-2,880
| -25% | -$105K | ﹤0.01% | 4540 |
|
|
2020
Q2 | $379K | Buy |
11,507
+5,208
| +83% | +$172K | ﹤0.01% | 4390 |
|
|
2020
Q1 | $163K | Buy |
6,299
+5,423
| +619% | +$140K | ﹤0.01% | 4629 |
|
|
2019
Q4 | $27K | Buy |
+876
| New | +$27K | ﹤0.01% | 5389 |
|